This page shows the latest Akorn Pharma news and features for those working in and with pharma, biotech and healthcare.
External ‘experts’ are investigating alleged breaches of data integrity requirements. Fresenius Kabi says its $4.3bn deal to acquire US generic drugmaker Akorn Pharma could be scuppered by an FDA probe ... period of 2016, with the declines all coming
Fresenius is paying $34 per share for Akorn - valuing the company at $4.3bn - and will also assume around $450m in debt held by the US firm. ... Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...